BBA Reviews on Cancer covers the whole field of the biology and biochemistry of cancer, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signalling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. In short, the Journal presents critical invited reviews on new developments in cancer investigation at the molecular level.
Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.
Cancer Discovery is the one-stop source for information in cancer science and medicine. The journal includes the following sections: News, Research Watch, Views, Mini Reviews, Reviews, Research Briefs, and Research Articles.
Cancer Research publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience spanning basic, preclinical, clinical, prevention, and epidemiologic research. Cancer Research seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. The main scope of the Journal is captured in its primary subsections, which focus on integrated systems and technology, microenvironment and immunology, molecular and cellular pathobiology, prevention and epidemiology, therapeutics and targets, and tumor and stem cell biology.
Nature Reviews Clinical Oncology's clinical content is written by internationally renowned clinical academics and researchers and targeted towards readers in the medical sciences, from postgraduate level upwards. While intended to be read by practicing doctors, researchers and academics within a specialty, we aim to make all our articles accessible to readers working in any medical discipline.
The Journal of the National Cancer Institute (JNCI) publishes peer-reviewed original research from around the world and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. For the past several years, the JNCI has been ranked as one of the most-cited original-research cancer journals by the Institute of Scientific Information in its annual Journal Citation Reports.
Cancer Cell provides a high-profile forum to promote major advances in cancer research and oncology. The primary criterion for considering papers is whether the studies provide major advances into answering the important questions relevant to naturally occurring cancers.
The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice.
Nature Reviews Cancer will be a gateway from which cancer researchers — from those investigating the molecular basis of cancer to those involved in translational research — access the information that they need to further the ability to diagnose, treat and ultimately prevent cancer.
Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.